Symbicort Turbuhaler 60MD: Advanced Control for Asthma and COPD
| Product dosage: 100 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $46.31 | $46.31 (0%) | 🛒 Add to cart |
| 2 | $36.74 | $92.62 $73.49 (21%) | 🛒 Add to cart |
| 3 | $32.21
Best per inhaler | $138.93 $96.64 (30%) | 🛒 Add to cart |
| Product dosage: 200 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $50.34 | $50.34 (0%) | 🛒 Add to cart |
| 2 | $45.81 | $100.67 $91.61 (9%) | 🛒 Add to cart |
| 3 | $41.28
Best per inhaler | $151.01 $123.83 (18%) | 🛒 Add to cart |
| Product dosage: 400 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $55.37 | $55.37 (0%) | 🛒 Add to cart |
| 2 | $50.34 | $110.74 $100.67 (9%) | 🛒 Add to cart |
| 3 | $44.30
Best per inhaler | $166.11 $132.89 (20%) | 🛒 Add to cart |
Synonyms | |||
Symbicort Turbuhaler 60MD is a combination maintenance inhaler designed for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients—budesonide, an inhaled corticosteroid that reduces airway inflammation, and formoterol, a long-acting beta2-agonist that relaxes airway muscles. This dual-action formulation helps prevent symptoms, improve lung function, and reduce exacerbation frequency. The Turbuhaler device offers consistent, breath-actuated delivery, making it a cornerstone of modern respiratory care for appropriate patients under medical supervision.
Features
- Contains budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per inhalation
- Delivers 60 metered doses per inhaler
- Breath-actuated Turbuhaler device requires no hand-breath coordination
- Built-in dose counter to track remaining medication
- Does not require shaking before use
- Dry powder formulation, free of propellants
Benefits
- Provides dual therapy to simultaneously reduce inflammation and bronchoconstriction
- Helps achieve and maintain long-term control of respiratory symptoms
- Reduces frequency and severity of asthma and COPD exacerbations
- Improves overall lung function and quality of life measurements
- Convenient twice-daily dosing regimen supports treatment adherence
- Rapid-onset bronchodilation from formoterol component
Common use
Symbicort Turbuhaler 60MD is indicated for the maintenance treatment of asthma in patients aged 12 years and older where combination therapy is appropriate. It is also approved for the maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. For asthma management, it should be used regularly rather than for immediate relief of acute symptoms. In severe COPD, it helps reduce exacerbations and improve symptom control.
Dosage and direction
For asthma maintenance: The recommended dose is 2 inhalations twice daily (morning and evening). For COPD maintenance: The recommended dose is 2 inhalations twice daily. Patients should rinse their mouth with water after inhalation to reduce the risk of oral candidiasis. The Turbuhaler should be held upright during loading and administration. Twist the grip fully in one direction and then back until it clicks to load a dose. Breathe out gently away from the mouthpiece, place lips firmly around it, and inhale deeply and forcefully. Do not exhale into the device.
Precautions
Patients should be monitored for increased use of short-acting beta2-agonists, which may indicate deteriorating asthma control. Systemic effects of corticosteroids may occur, particularly at high doses over prolonged periods. Caution is advised in patients with tuberculosis, fungal, bacterial, or viral infections. Osteoporosis may be accelerated with long-term high-dose corticosteroid therapy. Patients should be advised that Symbicort is not for relief of acute bronchospasm and should have a separate rescue inhaler available.
Contraindications
Hypersensitivity to budesonide, formoterol, or any component of the formulation. Not indicated for the primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. Should not be used more frequently than recommended or at higher doses than prescribed due to risk of excessive pharmacologic effects.
Possible side effects
Common side effects (≥1/100) include headache, oral candidiasis, hoarseness/dysphonia, throat irritation, and cough. Uncommon side effects (≥1/1,000) include palpitations, tachycardia, muscle cramps, anxiety, tremors, and dermatological reactions. Rare systemic effects of corticosteroids may include adrenal suppression, reduced bone mineral density, cataracts, and glaucoma. Paradoxical bronchospasm may occur immediately after inhalation requiring alternative therapy.
Drug interaction
Concomitant use with other beta-adrenergic drugs may potentiate sympathetic effects. Ketoconazole and other potent CYP3A4 inhibitors may increase budesonide plasma concentrations. Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate the cardiovascular effects of formoterol. Beta-blockers may antagonize the effects of formoterol and produce severe bronchospasm in patients with asthma. QT-prolonging agents may increase the risk of ventricular arrhythmias when used with formoterol.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. Patients should maintain the regular dosing schedule and contact their healthcare provider if multiple doses are missed or if symptoms worsen.
Overdose
Overdosage may produce symptoms consistent with beta2-agonist overdose including tachycardia, arrhythmias, tremor, headache, and hypokalemia. Corticosteroid overdose may produce hypercorticism. Treatment should be supportive and symptomatic. Cardiac monitoring is recommended in cases of significant overdose. Serum potassium should be monitored due to risk of hypokalemia.
Storage
Store at room temperature (15-30°C/59-86°F) in a dry place. Keep the lid tightly closed when not in use. Do not store in moist areas such as bathrooms. Discard 3 months after opening or when the dose counter reads “0,” whichever comes first. Do not puncture or incinerate even after use. Keep out of reach of children.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment decisions. Dosage and administration should be determined by a physician based on individual patient needs and response. Patients should not adjust their medication regimen without medical supervision.
Reviews
Clinical studies demonstrate that Symbicort Turbuhaler 60MD significantly improves lung function (FEV1) compared to monotherapy components alone. In asthma trials, patients experienced fewer exacerbations and improved symptom scores. COPD studies showed reduced exacerbation frequency and improved health status. Patients report satisfaction with the convenience of the Turbuhaler device and the effectiveness of symptom control. Healthcare providers appreciate the dual mechanism of action and the well-established safety profile when used as directed.